Halozyme Therapeutics (HALO) EPS (Basic) (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of EPS (Basic) data on file, last reported at $1.27 in Q1 2026.

• On a quarterly basis, EPS (Basic) rose 32.51% year-over-year to $1.27 in Q1 2026; TTM through Mar 2026 was $2.95, a 25.04% decrease from a year earlier, with the FY2025 full-year figure at $2.64, down 24.48% from the prior year.
• EPS (Basic) for Q1 2026 stood at $1.27, up from -$1.18 in the prior quarter.
• Over the last five years, EPS (Basic) for HALO reached as high as $1.5 in Q3 2025 and fell as low as -$1.18 in Q4 2025.
• Historically, EPS (Basic) has averaged $0.65 across 5 years, with a median of $0.62 in 2023.
• Across the five-year window, EPS (Basic) surged 245.06% in 2023 and slumped 209.37% in 2025, its largest moves.
• Year by year, EPS (Basic) stood at $0.42 in 2022, then surged by 53.5% to $0.65 in 2023, then jumped by 66.91% to $1.08 in 2024, then plunged by 209.37% to -$1.18 in 2025, then soared by 207.49% to $1.27 in 2026.
• Per Business Quant data, the three most recent EPS (Basic) figures were $1.27 in Q1 2026, -$1.18 in Q4 2025, and $1.5 in Q3 2025.